THC Tenet Healthcare (THC) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-general medical & surgical hospitals, nec · CIK 0000070318
Congress · 1Form 144 · 11
Insider buyers, 180 days
0
Funds added, last quarter
343
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · no price filed
What the filings say about THC
Insiders, 180 days
-$51.5M net sold
11 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-04-20
Planned sales (Form 144), 90 days
$45.2M
11 notices
Tenet Healthcare insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, TENET HEALTHCARE CORP insiders sold a net $51.5M of stock across 137 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on May 28, 2026.
- The trade is 48.4% of the 11,321 shares held after it.
- 5 other insiders sold within 30 days.
- 343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KERREY J ROBERT sold about $1.4M of THC on Sep 14, 2026; 5 other insiders sold within 30 days and 343 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on May 28, 2026.
- The trade is 55.2% of the 7,296 shares held after it.
- 5 other insiders sold within 30 days.
- 343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KERREY J ROBERT sold about $1.1M of THC on Sep 14, 2026; 5 other insiders sold within 30 days and 343 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on May 28, 2026.
- The trade is 52.2% of the 4,794 shares held after it.
- 5 other insiders sold within 30 days.
- 343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director KERREY J ROBERT sold about $662.1K of THC on Sep 14, 2026; 5 other insiders sold within 30 days and 343 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 12, 2024.
- The trade is 39.8% of the 25,121 shares held after it.
- 5 other insiders sold within 30 days.
- 343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MARK RICHARD J sold about $2.6M of THC on Sep 10, 2026; 5 other insiders sold within 30 days and 343 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 27, 2026.
- The trade is 4.9% of the 23,653 shares held after it.
- 7 other insiders sold within 30 days.
- 343 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director West Nadja sold about $298.1K of THC on Sep 2, 2026; 7 other insiders sold within 30 days and 343 funds added in the latest 13F quarter.137 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$51.5M over 180 days
-$45.2M over 90 days
below 84% of Healthcare Services
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
343 funds bought in last quarter
more than 92% of Healthcare Services
Revenue
+3.1% year over year
below 72% of Healthcare Services
Margin
11.1% net margin
more than 92% of Healthcare Services
Buybacks
$1.4B repurchased, FY to 2026-06-30
more than 97% of Healthcare Services
Short interest
2.3% of the float short (float per yahoo 2026-10-26) · 2.1 days to cover · settled 2026-09-30
below 60% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch THC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+26.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns THC: institutional holders (13F)
13F holdings, latest reported quarter
8,743,005 sh
$1.6B
4,433,360 sh
$829.1M
4,238,108 sh
$792.9M
3,994,545 sh
$747.3M
3,894,189 sh
$728.5M
Congress trades in THC
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-04-20 · disclosed 37 days later
$15,001 - $50,000
Sold 2026-04-15 · disclosed 42 days later
$1,001 - $15,000
Sold 2026-02-11 · disclosed 29 days later
$1,001 - $15,000
Bought 2025-12-10 · disclosed 29 days later
$15,001 - $50,000
Bought 2025-09-03 · disclosed 42 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
THC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
KERREY J ROBERT
Filed 2026-09-14
$3.2M
MARK RICHARD J
Filed 2026-09-10
$2.6M
West Nadja
Filed 2026-09-02
$298.1K
Foo Lisa Y
Filed 2026-08-31
$6.4M
Sutaria Saumya
Filed 2026-08-25
$13.7M
THC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Huber Mid Cap Value Fund
$637.0K position · as of 2026-07-31
5.0%
TEXAS CAPITAL TEXAS EQUITY INDEX ETF
$1.5M position · as of 2026-06-30
4.1%
Concourse Capital Focused Equity ETF
$1.4M position · as of 2026-05-29
3.6%
Huber Select Large Cap Value Fund
$16.5M position · as of 2026-07-31
3.3%
Castellan Targeted Equity ETF
$20.0M position · as of 2026-05-29
3.3%
Timothy Plan Free Cash Flow ETF
$1.3M position · as of 2026-06-30
3.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Tenet Healthcare Corporation Political Action Committee
Cycle 2026 · $165K spent
$283.8K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Dr.Sutaria
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$24.7M
$88.9M
$4.8M
+216%
+29%
2023
$18.5M
$63.9M
$4.7M
+89%
+26%
2022
$11.0M
-$9.1M
$6.9M
+22%
+24%
2020
$16.7M
$16.1M
$5.0M
+5%
+13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $51.5M sold by insiders over 180 days, 343 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $45.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
THC financials
Revenue growth
+3.1%
XBRL, annual
Net margin
11.1%
Complaints, 90 days
2
- YoY · CFPB
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.8B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM THC
| FY Dec 2025 | $21.3B |
| FY Dec 2024 | $20.7B |
| FY Dec 2023 | $20.6B |
| FY Dec 2022 | $19.2B |
| FY Dec 2021 | $19.5B |
| Jun 2026 | $5.6B |
| Mar 2026 | $5.4B |
| Dec 2025 | $5.5B |
| Sep 2025 | $5.3B |
| Jun 2025 | $5.3B |
| Mar 2025 | $5.2B |
| Dec 2024 | $5.1B |
| Sep 2024 | $5.1B |
At each fiscal year end
Single quarter
Net margin, TTM
+14.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM THC
| FY Dec 2025 | +11.1% |
| FY Dec 2024 | +19.7% |
| FY Dec 2023 | +6.4% |
| FY Dec 2022 | +5.2% |
| FY Dec 2021 | +7.6% |
| Jun 2026 | +18.6% |
| Mar 2026 | +16.9% |
| Dec 2025 | +11.7% |
| Sep 2025 | +10.9% |
| Jun 2025 | +9.9% |
| Mar 2025 | +11.9% |
| Dec 2024 | +11.3% |
| Sep 2024 | +13.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.0B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM THC
| FY Dec 2025 | $2.5B |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $1.6B |
| FY Dec 2022 | $321.0M |
| FY Dec 2021 | $910.0M |
| Jun 2026 | $417.0M |
| Mar 2026 | $1.5B |
| Dec 2025 | $367.0M |
| Sep 2025 | $778.0M |
| Jun 2025 | $743.0M |
| Mar 2025 | $642.0M |
| Dec 2024 | -$661.0M |
| Sep 2024 | $829.0M |
At each fiscal year end
Single quarter
Debt to equity
2.81x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity THC
| FY Dec 2025 | 3.10x |
| FY Dec 2024 | 3.14x |
| FY Dec 2023 | 9.25x |
| FY Dec 2022 | 13.08x |
| FY Dec 2021 | 15.09x |
| Jun 2026 | 2.81x |
| Mar 2026 | 2.73x |
| Dec 2025 | 3.10x |
| Sep 2025 | 3.26x |
| Jun 2025 | 3.49x |
| Mar 2025 | 3.13x |
| Dec 2024 | 3.14x |
| Sep 2024 | 3.33x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.31x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt THC
| FY Dec 2025 | 0.27x |
| FY Dec 2024 | 0.16x |
| FY Dec 2023 | 0.16x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.10x |
| Jun 2026 | 0.31x |
| Mar 2026 | 0.33x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.16x |
| Sep 2024 | 0.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+75.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity THC
| FY Dec 2025 | +56.4% |
| FY Dec 2024 | +140.6% |
| FY Dec 2023 | +95.3% |
| FY Dec 2022 | +92.3% |
| FY Dec 2021 | +279.5% |
| Jun 2026 | +75.5% |
| Mar 2026 | +58.9% |
| Dec 2025 | +56.4% |
| Sep 2025 | +58.5% |
| Jun 2025 | +66.4% |
| Mar 2025 | +61.6% |
| Dec 2024 | +140.6% |
| Sep 2024 | +149.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+10.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets THC
| FY Dec 2025 | +8.1% |
| FY Dec 2024 | +14.2% |
| FY Dec 2023 | +4.7% |
| FY Dec 2022 | +3.7% |
| FY Dec 2021 | +5.4% |
| Jun 2026 | +10.7% |
| Mar 2026 | +8.8% |
| Dec 2025 | +8.1% |
| Sep 2025 | +7.8% |
| Jun 2025 | +8.3% |
| Mar 2025 | +8.1% |
| Dec 2024 | +14.2% |
| Sep 2024 | +13.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+25.0%
operating income after a 17.9% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital THC
| FY Dec 2025 | +20.7% |
| FY Dec 2024 | +33.3% |
| FY Dec 2023 | +13.4% |
| FY Dec 2022 | +12.1% |
| FY Dec 2021 | +16.5% |
| Jun 2026 | +25.0% |
| Mar 2026 | +22.1% |
| Dec 2025 | +20.7% |
| Sep 2025 | +21.3% |
| Jun 2025 | +21.2% |
| Mar 2025 | +20.5% |
| Dec 2024 | +33.3% |
| Sep 2024 | +35.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+18.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed THC
| FY Dec 2025 | +14.1% |
| FY Dec 2024 | +24.7% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +10.3% |
| FY Dec 2021 | +12.8% |
| Jun 2026 | +18.3% |
| Mar 2026 | +15.5% |
| Dec 2025 | +14.1% |
| Sep 2025 | +14.3% |
| Jun 2025 | +15.3% |
| Mar 2025 | +15.0% |
| Dec 2024 | +24.7% |
| Sep 2024 | +25.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
10.11x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing THC
| FY Dec 2025 | 12.84x |
| FY Dec 2024 | 3.90x |
| FY Dec 2023 | 13.23x |
| FY Dec 2022 | 12.98x |
| FY Dec 2021 | 9.70x |
| Jun 2026 | 7.22x |
| Mar 2026 | 9.82x |
| Dec 2025 | 12.84x |
| Sep 2025 | 13.81x |
| Jun 2025 | 11.19x |
| Mar 2025 | 8.83x |
| Dec 2024 | 3.90x |
| Sep 2024 | 5.33x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$32.0B
market value at close 2026-10-27 on 2026-07-24 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value THC
| FY Dec 2025 | $27.7B |
| FY Dec 2024 | $22.1B |
| FY Dec 2023 | $21.3B |
| FY Dec 2022 | $19.4B |
| FY Dec 2021 | $21.9B |
| Jun 2026 | $27.0B |
| Mar 2026 | $26.6B |
| Dec 2025 | $27.7B |
| Sep 2025 | $28.1B |
| Jun 2025 | $26.8B |
| Mar 2025 | $22.9B |
| Dec 2024 | $22.1B |
| Sep 2024 | $24.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+14.3%
TTM free cash flow over market value at close 2026-10-27
FCF yield THC
| FY Dec 2025 | +14.5% |
| FY Dec 2024 | +9.3% |
| FY Dec 2023 | +21.1% |
| FY Dec 2022 | +6.1% |
| FY Dec 2021 | +10.4% |
| Jun 2026 | +18.8% |
| Mar 2026 | +20.4% |
| Dec 2025 | +14.5% |
| Sep 2025 | +8.4% |
| Jun 2025 | +9.5% |
| Mar 2025 | +11.0% |
| Dec 2024 | +9.3% |
| Sep 2024 | +15.0% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.16x
P/E over trailing EPS growth of 65%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing THC
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.26x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.08x |
| Jun 2026 | 0.11x |
| Mar 2026 | 0.37x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $21.3B | $20.7B | $20.6B | $19.2B |
| Operating income | $3.5B | $6.0B | $2.5B | $2.3B |
| Net income | $2.4B | $4.1B | $1.3B | $1.0B |
| EPS (diluted) | 15.49 | 32.70 | 5.71 | 3.79 |
| Operating cash flow | $3.5B | $2.0B | $2.4B | $1.1B |
| Cash | $2.9B | $3.0B | $1.2B | $858.0M |
| Long-term debt | $13.1B | $13.1B | $14.9B | $14.9B |
| Buybacks | $1.4B | $672.0M | $200.0M | $250.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
THC Stock Sonar score 6/7 axes
Find similar shapesCompareTHC ranks highest on profitability (90th percentile) and institutional and government (75th), and lowest on insider conviction (7th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
THC filings, in plain words
Are Tenet Healthcare insiders buying or selling THC?
In the 180 days to 2026-10-28, Tenet Healthcare insiders were net sellers, a net $51.5M across purchases and sales reported on Form 4, by 11 sellers.
Have members of Congress traded THC?
Yes. In the year to 2026-10-28, 1 House member disclosed buying THC and 1 House member disclosed selling it; the latest on record is a sale by Jonathan Jackson dated 2026-04-20.
Are there planned insider sales of THC?
Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $45.2M of stock; the latest, by KERREY J ROBERT, was filed 2026-09-14.
Read the full summary
In the 180 days to 2026-10-28, Tenet Healthcare insiders were net sellers of THC, a net $51.5M across purchases and sales reported on Form 4 by 11 sellers. None of the 25 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying THC and 1 member disclosed selling it; the latest on record is a sale by Jonathan Jackson dated 2026-04-20. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $45.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
